Anthrax disease is a severe bacterial infection caused by Bacillus anthracis. This ailment is predominantly seen in livestock and some wild animals. But it can also be transmitted to humans when they come in contact with the infected animals. Anthrax can be easily used as a biological weapon as it can be produced in lab and is also easily found in nature. The common symptoms include rashes, digestion issues, cold, fever, loss of appetite, and shortness of breath, among others.
Established in 1897 by Fairleigh S. Dickinson and Maxwell Becton, the company has its headquarters in Franklin Lakes, New Jersey, United States. It focuses on improving medical discovery, diagnostics, and the delivery of care.
BD has played a role in providing anthrax disease diagnostic solutions. It offers culture media, testing kits, and laboratory equipment designed to detect and confirm the presence of Bacillus anthracis in clinical samples. These tools aid healthcare professionals in quickly and accurately diagnosing anthrax, allowing for timely intervention and public health measures.
Founded in 1989, the company has its headquarters in Princeton, New Jersey, United States. Richard Caruso is the founding father of this medical device manufacturing firm.
Integra is known for its innovative solutions in the healthcare industry, providing a range of medical devices and instruments to support surgical procedures and improve patient outcomes. It has predominantly contributed to the development of diagnostic tools and technologies for various diseases, including infectious ones like anthrax.
This for-profit private hospital network was established in 1996 by Shivinder Mohan Singh and Malvinder Mohan Singh. Its headquarters are situated in Gurugram, India. It is known for offering a plethora of healthcare services.
With context to anthrax diagnosis, Fortis develops relevant scientific equipment, tools, and technologies. It is also involved in R&D activities pertaining to such severe ailments.
Based in Parsippany-Troy Hills, New Jersey, United States, this biotech company was established in 1998. It is predominantly known for its work in creating novel therapeutic solutions to address public health concerns, particularly related to biodefense and emerging infectious diseases.
Elusys has been working on an anthrax antitoxin called Anthim (obiltoxaximab), which is a monoclonal antibody designed to neutralize the toxins produced by Bacillus anthracis.
Headquartered in Winnipeg, Canada, the company was set up in 1984. It specializes in the development and manufacturing of biopharmaceutical products, particularly immunotherapies and specialty plasma-derived therapies.
Cangene Corporation has been associated with the development of an anthrax immune globulin called Anthrasil. Anthrasil is a hyperimmune product designed to provide passive immunity by supplying antibodies against the toxins produced by Bacillus anthracis, the bacterium that causes anthrax.
Several key players, such as Becton, Dickinson and Company, Integra LifeSciences, Elusys Therapeutics, and Cangene Corporation, have been at the forefront of revolutionizing the business sphere related to anthrax disease. These companies contribute significantly to the diagnosis and treatment of anthrax, showcasing innovation and dedication in the field of medical technology, biopharmaceuticals, and healthcare services. Through the development of diagnostic tools, therapeutic antibodies, and hyperimmune products, these industry leaders play a crucial role in enhancing the capabilities of the healthcare sector to address the challenges posed by infectious diseases like anthrax. Their ongoing research, collaborations, and advancements continue to shape the landscape of anthrax disease management, emphasizing the importance of a comprehensive and proactive approach in safeguarding public health.